title: Role of withdrawal in reinstatement of morphine-conditioned place preference.
abstract: BACKGROUND
  Relapse is a major characteristic of drug addiction and the primary problem in treating drug abuse. Based on the negative reinforcement view of addiction, in which the motivation to take drugs is thought to result from the desire to avoid the aversive effect of drug withdrawal, it has been theorized that withdrawal symptoms play a major role in the maintenance of and relapse to drug taking. However, the role of withdrawal in relapse has not yet been systemically investigated in the reinstatement model.
  
  
  OBJECTIVE
  Using a conditioned place preference (CPP) paradigm, we examined the role of different morphine withdrawal states (spontaneous withdrawal, naloxone-precipitated withdrawal, and conditioned withdrawal) in relapse to drug seeking.
  
  
  METHODS
  Rats alternately received morphine (10 mg/kg, s.c.) and saline for 8 days to acquire the CPP. The morphine CPP disappeared after a 2-week extinction phase of saline-paired training. Rats were then chronically administered morphine to induce physical dependence. The different withdrawal states were induced and their roles in the reinstatement of extinguished CPP were assessed. During conditioned withdrawal, trunk blood samples were taken and the corticosterone level was measured by radioimmunoassay. To examine the role of corticotropin-releasing factor (CRF) receptor antagonist on conditioned-withdrawal-induced reinstatement of CPP, different doses of alpha-helical CRF (0.1 and 1 mug, i.c.v.) were administered 30 min prior to the CPP testing.
  
  
  RESULTS
  The results show that morphine spontaneous withdrawal and naloxone-precipitated morphine withdrawal were ineffective in reinstatement morphine CPP. However, the withdrawal cues significantly elicited the reinstatement of CPP and increased corticosterone level. Moreover, pretreatment with the CRF receptor antagonist alpha-helical CRF (1 mug, i.c.v.) significantly attenuated the effects of withdrawal cues on reinstatement of CPP and corticosterone levels.
  
  
  CONCLUSIONS
  These findings demonstrate that the cues associated with previous drug withdrawal play a major role in drug relapse and that activation of the CRF receptor is involved in conditioned-withdrawal-induced reinstatement. The present study suggests that CRF receptor antagonists might be of value in the treatment and prevention of relapse to drug seeking after long-term abstinence.
authors.affiliation: National Laboratory of Medical Neurobiology and Pharmacology Research Center, Fudan University, 138 Yi Xue Yuan Road, Shanghai 200032, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Lu
authors.forename: Hai
authors.initials: H
authors.lastname: Chen
authors.forename: Wenjuan
authors.initials: W
authors.lastname: Su
authors.forename: Xin
authors.initials: X
authors.lastname: Ge
authors.forename: Wen
authors.initials: W
authors.lastname: Yue
authors.forename: Fen
authors.initials: F
authors.lastname: Su
authors.forename: Lan
authors.initials: L
authors.lastname: Ma
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D003213:Conditioning, Psychological / Q000187:drug effects*; D003346:Corticotropin-Releasing Hormone / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006727:Hormone Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D007276:Injections, Intraventricular; D007279:Injections, Subcutaneous; D008297:Male; D009020:Morphine / Q000008:administration & dosage / Q000494:pharmacology*; D009021:Morphine Dependence / Q000503:physiopathology*; D009270:Naloxone / Q000008:administration & dosage / Q000494:pharmacology; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology; D011863:Radioimmunoassay / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors / Q000502:physiology; D012054:Reinforcement, Psychology; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology*
chemical_list: D006727:Hormone Antagonists; D010446:Peptide Fragments; D018019:Receptors, Corticotropin-Releasing Hormone; D009270:Naloxone; D009020:Morphine; D003346:Corticotropin-Releasing Hormone; C045089:corticotropin releasing hormone (9-41)
references.citation: Psychopharmacology (Berl). 1989;97(1):59-64
references.pmid: 2496428
references.citation: Brain Res. 2002 Sep 20;950(1-2):1-9
references.pmid: 12231223
references.citation: J Psychiatry Neurosci. 2000 Mar;25(2):125-36
references.pmid: 10740986
references.citation: Prog Neurobiol. 1998 Dec;56(6):613-72
references.pmid: 9871940
references.citation: Neurosci Biobehav Rev. 2003 Aug;27(5):457-91
references.pmid: 14505687
references.citation: Psychopharmacology (Berl). 2000 Dec;153(1):31-43
references.pmid: 11255927
references.citation: Fed Proc. 1985 Jan;44(1 Pt 2):259-63
references.pmid: 3871412
references.citation: Nat Rev Neurosci. 2001 Feb;2(2):119-28
references.pmid: 11252991
references.citation: Psychopharmacology (Berl). 2003 Jul;168(1-2):3-20
references.pmid: 12402102
references.citation: Science. 1997 Oct 3;278(5335):66-70
references.pmid: 9311929
references.citation: N Engl J Med. 1988 May 5;318(18):1173-82
references.pmid: 3283549
references.citation: Psychol Rev. 1974 Mar;81(2):119-45
references.pmid: 4817611
references.citation: Nature. 2000 Jun 29;405(6790):1013-4
references.pmid: 10890431
references.citation: Brain Res Brain Res Rev. 1997 Dec;25(3):359-72
references.pmid: 9495563
references.citation: Behav Brain Res. 2000 Oct;115(1):39-47
references.pmid: 10996406
references.citation: Behav Brain Res. 2002 Nov 15;136(2):389-97
references.pmid: 12429400
references.citation: Br J Addict. 1992 Aug;87(8):1133-44
references.pmid: 1511227
references.citation: Pharmacol Rev. 2002 Mar;54(1):1-42
references.pmid: 11870259
references.citation: J Neurochem. 2000 Jan;74(1):199-208
references.pmid: 10617121
references.citation: Science. 1981 Sep 18;213(4514):1394-7
references.pmid: 6267699
references.citation: Pharmacol Rev. 2001 Jun;53(2):209-43
references.pmid: 11356984
references.citation: Annu Rev Pharmacol Toxicol. 1996;36:359-78
references.pmid: 8725394
references.citation: Neuroreport. 2000 Aug 3;11(11):2373-8
references.pmid: 10943688
references.citation: Psychopharmacology (Berl). 1999 Jul;145(1):21-30
references.pmid: 10445369
references.citation: Psychol Rev. 1984 Apr;91(2):251-68
references.pmid: 6571424
references.citation: Neuropsychopharmacology. 1996 Nov;15(5):497-505
references.pmid: 8914123
references.citation: Eur J Neurosci. 2000 Dec;12(12):4398-404
references.pmid: 11122350
references.citation: Psychopharmacology (Berl). 1995 Jun;119(3):334-41
references.pmid: 7675970
references.citation: Br J Pharmacol. 1996 Sep;119(1):174-82
references.pmid: 8872371
references.citation: Neuropsychopharmacology. 2003 May;28(5):865-71
references.pmid: 12736632
references.citation: Brain Res. 1995 Mar 27;675(1-2):89-97
references.pmid: 7796157
references.citation: Eur J Pharmacol. 2001 Dec 7;432(2-3):153-61
references.pmid: 11740951
references.citation: Drug Alcohol Depend. 1998 Jun-Jul;51(1-2):23-47
references.pmid: 9716928
references.citation: Neuroscience. 2003;119(2):497-505
references.pmid: 12770563
references.citation: Psychopharmacology (Berl). 2000 Oct;152(2):140-8
references.pmid: 11057517
references.citation: Pavlov J Biol Sci. 1979 Jul-Sep;14(3):170-6
references.pmid: 45498
references.citation: Brain Res Brain Res Rev. 2000 Aug;33(1):13-33
references.pmid: 10967352
references.citation: Ann N Y Acad Sci. 1999;897:27-45
references.pmid: 10676433
references.citation: Brain Res Mol Brain Res. 1998 Apr;55(2):221-31
references.pmid: 9582424
references.citation: Psychopharmacologia. 1976;46(1):19-25
references.pmid: 1257363
references.citation: Brain Res. 1988 Dec 6;474(2):364-8
references.pmid: 2463060
references.citation: Am J Psychiatry. 1999 Jan;156(1):11-8
references.pmid: 9892292
references.citation: Science. 1997 Oct 3;278(5335):52-8
references.pmid: 9311926
references.citation: Ann N Y Acad Sci. 1994 Oct 31;739:176-84
references.pmid: 7832471
references.citation: Psychopharmacology (Berl). 2002 Jan;159(2):125-32
references.pmid: 11862339
references.citation: Psychiatr Clin North Am. 1986 Sep;9(3):413-25
references.pmid: 3534813
references.citation: Neurosci Lett. 2000 Sep 22;291(3):191-5
references.pmid: 10984639
references.citation: Psychopharmacology (Berl). 1983;79(1):29-31
references.pmid: 6403961
references.citation: Am J Addict. 2001;10 Suppl:3-15
references.pmid: 11268820
references.citation: Am J Psychiatry. 1948 Nov;105(5):329-38
references.pmid: 18890902
references.citation: J Neurosci. 1996 Mar 1;16(5):1957-63
references.pmid: 8774462
references.citation: Brain Res. 2001 Jul 20;908(1):86-92
references.pmid: 11457434
references.citation: Psychoneuroendocrinology. 1997 May;22(4):237-59
references.pmid: 9226728
references.citation: Brain Res Bull. 1989 Oct-Nov;23(4-5):373-87
references.pmid: 2556210
references.citation: Pharmacol Biochem Behav. 2002 Mar;71(3):517-29
references.pmid: 11830186
references.citation: Nat Neurosci. 2001 Sep;4(9):943-7
references.pmid: 11528427
references.citation: J Pharmacol Exp Ther. 2002 Jun;301(3):785-9
references.pmid: 12023504
references.citation: Ann N Y Acad Sci. 1992 Jun 28;654:400-15
references.pmid: 1632593
references.citation: Am J Psychiatry. 1991 Dec;148(12):1712-6
references.pmid: 1957935
references.citation: Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):12040-5
references.pmid: 8876259
references.citation: Neurosci Biobehav Rev. 1995 Spring;19(1):39-51
references.pmid: 7770196
references.citation: Neurosci Biobehav Rev. 1989 Summer-Fall;13(2-3):135-40
references.pmid: 2682399
references.citation: Psychopharmacologia. 1967;10(3):255-84
references.pmid: 5626647
references.citation: Neuropharmacology. 2004;47 Suppl 1:167-79
references.pmid: 15464135
references.citation: J Neurochem. 2003 Jun;85(6):1604-13
references.pmid: 12787079
references.citation: Neuropharmacology. 1992 Dec;31(12):1231-41
references.pmid: 1335131
references.citation: Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91
references.pmid: 8401595
references.citation: J Abnorm Psychol. 1988 May;97(2):118-32
references.pmid: 3290303